AOD-9604

AOD-9604 spray provides the same tyrosine-extended hGH 177-191 peptide as our vial product, in solution in a spray bottle, for laboratories working on peptide formulation and non-injected delivery. Nasal and nose-to-brain delivery of peptides is an active preclinical research area because peptides have low metabolic stability, cross the blood-brain barrier poorly and are poorly suited to oral administration. AOD-9604 itself has been characterized in serum and urine stability studies and in obese-mouse studies of fat oxidation. Research Market supplies each lot with identity and purity data on its certificate of analysis. It is sold strictly for laboratory research use.

Chemical structure and identification

• Molecular formula: C₇₈H₁₂₃N₂₃O₂₃S₂
• Molecular weight: 1815.1 g/mol
• CAS number: 221231-10-3
• PubChem CID: 71300630
• Amino acid sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF; hGH 177-191 with an added N-terminal Tyr, Cys7–Cys14 disulfide)
• Synonyms: AOD 9604, AOD-9604
• Form: Supplied in solution in a spray bottle

Research applications

• Stability in biological matrices: When AOD9604 was incubated in serum and urine, six metabolites were identified; a single fragment, CRSVEGSCG, was markedly more stable than the parent peptide and the other metabolites [1]
• Nasal aerosol delivery of peptides: Reviewed nose-to-brain delivery of peptides as nasal aerosols, which uses the olfactory and trigeminal nerve pathways to reach the brain while bypassing the blood-brain barrier, along with nasal delivery devices and the limits of the approach [2]
• Nanocarrier formulations: Reviewed polymer- and lipid-based nanocarriers, biorecognitive ligands and permeation enhancers studied for direct nose-to-brain transport of peptide and protein drugs, noting the field’s early stage [3]
• Receptor pharmacology: AOD9604 did not compete for the hGH receptor or drive hGH receptor-dependent cell proliferation in vitro, while increasing fat oxidation in obese mice [4]

Reference citations

1. Cox H.D. et al. (2015). Detection and in vitro metabolism of AOD9604. Drug Test Anal, 7(1):31–38. PMID 25208511 · DOI
2. Alabsi W. et al. (2022). Nose-to-brain delivery of therapeutic peptides as nasal aerosols. Pharmaceutics, 14(9):1870. PMID 36145618 · DOI
3. Samaridou E. et al. (2018). Nose-to-brain peptide delivery – the potential of nanotechnology. Bioorg Med Chem, 26(10):2888–2905. PMID 29170026 · DOI
4. Heffernan M.A. et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord, 25(10):1442–1449. PMID 11673763 · DOI

Compound data from PubChem CID 71300630. Literature summaries describe published preclinical research and are not claims about this product’s effects in humans or animals.